Loading data for ASND — first visit, this takes a few seconds.
Ascendis Pharma A/S (ASND)
NasdaqGS: ASND
· 即時價格 · USD
262.46
+1.23 (0.47%)
收盤價： Sep 11, 2026, 3:59 PM
263.52
+0.00%
盤後: 7:52 PM
股價、關鍵數字和最新消息，都在這一頁。
Ascendis Pharma A/S（ASND）股價、分析與資料
0.47% (1D)
| 買價 | 261.34 |
| 市值 | 17.3B |
| 營收 (ttm) | 1.05B |
| 淨利（ttm） | 742M |
| 0.00 | |
| 13.02 | |
| 20.24 | |
| 23.47 | |
| P/B (ttm) | 10.38 |
| P/S (ttm) | 16.56 |
| 財報日期 | Apr 30, 2026 |
| 賣價 | 281.59 |
| 成交量 | 20,081 |
| 20 日平均成交量 | 659,853 |
| 開盤價 | 263.34 |
| 前收盤價 | 261.23 |
| 當日區間 | 261.56 - 266.34 |
| 52 週範圍 | 186.05 - 282.15 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endo...
完整的公司簡介財務表現
Ascendis Pharma A/S 在 2025 年的營收為 720.13M，較前一年的 363.64M 增加 98.03%。 淨利為 -228.03M，較前期減少 -39.69%。
財務報表財報驚奇
Ascendis Pharma A/S 已於 Aug 13, 2026 公布季度財報：
- 營收為 $339.29M 低於預期 $0, 年增 114.68% 成長.
- 每股盈餘為 0.9 超出預期 0.13, 年增 240.63% 成長.
第 1 頁，共 2 頁